Defence Therapeutics Inc.

Recent News

  • Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated

    Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%. Defence used a variant of the AccumTM (the A1) to reprogram innate MSCs into antigen presenting cells. This "off-the-shelf"...

    2023-01-24 3:15 AM EST
  • RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023

    Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York Marriott Brooklyn Bridge in Brooklyn, New-York. IO360° offers...

    2023-01-23 3:15 AM EST
  • Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023

    Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York Marriott Brooklyn Bridge in Brooklyn, New-York. IO360° offers...

    2023-01-20 4:30 PM EST
  • Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP

    Vancouver, British Columbia--(Newsfile Corp. - January 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that that the United States Patent and Trademark Office (USPTO) has issued a Notice of allowance for their US patent application number 17/738,548. The allowed US patent application covers the use...

    2023-01-16 3:15 AM EST
  • mRNA with Defence's Accum(TM) Program Has Been Initiated

    Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program. This R&D program will not only impact the field of cancer immunotherapy, but it can also be directly applied to the development of new vaccines targeting infectious...

    2023-01-10 3:15 AM EST
  • Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors

    Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, just completed a pre-clinical study using its intranasal formulation of AccuTOXTM in the context of animals with pre-established lung cancer. The study shows that AccuTOXTM administration as a combination therapy with the immune-checkpoint inhibitor anti-PD1 reduces dramatically the level of lung nodules compared...

    2022-12-20 3:15 AM EST
  • Defence's mRNA with Accum(TM) for Cancer Vaccines Update

    Vancouver, British Columbia--(Newsfile Corp. - December 15, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its AccumTM technology with mRNA vaccination as previously announced in press release dated of October 31st, 2022. This R&D program will not only impact the field of cancer immunotherapy, but it can also be directly applied...

    2022-12-15 3:15 AM EST
  • Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately.Mr. Kwin Grauer, CPA, CA, has more than 20 years' experience operating, buying and selling small and medium-size businesses. Kwin is a seasoned professional in financing, financial...

    2022-12-09 3:30 PM EST